Abstract
Abstract Objective This study aimed to report the adverse drug events and treatment outcome of systemic linezolid therapy to manage multi-drug resistant orthopaedic surgical site infection in dogs. Materials and Methods Retrospective case review of four dogs that received linezolid to treat surgical site infections after orthopaedic surgery. Reevaluations consisted of a clinical examination or a telephone interview. Results Serum drug concentrations varied. All dogs showed a temporary resolution of clinical signs of surgical site infection. Two dogs that received linezolid at the previously reported dose developed drug-associated side effects. The side effects were anorexia, nausea, vomiting and regenerative anaemia. All side effects resolved after the discontinuation of linezolid. Surgical site infection recurred in two dogs 52 and 177 days after discontinuing linezolid respectively. Clinical significance Adverse drug events occurred in dogs receiving oral linezolid at the dosage of 10 to 20 mg/kg. Oral linezolid therapy failed to resolve deep orthopaedic surgical site infections in two out of four dogs. As a tertiary antimicrobial, linezolid should only be used in carefully selected cases while monitoring for drug-associated side effects.
Highlights
Linezolid is a synthetic oxazolidinone antimicrobial agent that inhibits protein synthesis by binding to ribosomal 50S subunits, which leads to inhibition of 70S subunit initiation and messenger ribonucleic acid translation.[1]
This study aimed to report the adverse drug events and treatment outcome of systemic linezolid therapy to manage multi-drug resistant orthopaedic surgical site infection in dogs
Linezolid should only be used in carefully selected cases while monitoring for drug-associated side effects
Summary
Linezolid is a synthetic oxazolidinone antimicrobial agent that inhibits protein synthesis by binding to ribosomal 50S subunits, which leads to inhibition of 70S subunit initiation and messenger ribonucleic acid translation.[1] Linezolid is an effective antimicrobial against multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus (MRS) and vancomycin-resistant Enterococcus species.[2] The use of linezolid has been reported in dogs for the treatment of MRS infections such as discospondylitis and deep pyoderma. The. Ã J.Y.’s current workplace is VCA West Coast Specialty and Emergency Animal Hospital, Orange County, California, United States. R.A.H-B’s current workplace is the Sam’s Clinic, Marin, California, United States. The purpose of this case series is to report the efficacy and adverse effects associated with long-term oral linezolid therapy for the treatment of resistant implant associated orthopaedic related surgical site infections (SSI) in four dogs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
